Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
Revenue (TTM)
$10 Mln
Net Profit (TTM)
$-2 Mln
ROE
-8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.8
Face value
--
Shares outstanding
15,847,517
CFO
$-77.59 Mln
EBITDA
$-77.72 Mln
Net Profit
$-177.35 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc (THMO)
| -- | -- | -- | -- | -96.6 | -93.9 | -81.2 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc (THMO)
| -99.9 | -81.3 | -93.0 | -51.7 | -52.5 | 64.9 | -91.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Thermogenesis Holdings Inc (THMO)
|
0.0 | 0.0 | 9.6 | -14.8 | -40.7 | -493.8 | -- | 0.0 |
| 46.7 | 10,201.5 | 6,708.0 | 373.9 | 7.8 | 8.7 | 29.7 | 2.5 | |
| 11.0 | 537.3 | 52.8 | -22.9 | -15.3 | -49 | -- | 7.8 | |
| 1,259.9 | 25,364.5 | 4,026.4 | 869.2 | 27.7 | -1154.9 | 29.7 | 1,328.2 | |
| 215.5 | 9,407.2 | 1,005.3 | 136.8 | 15.2 | 6.8 | 68.1 | 4.7 | |
| 13.7 | 524.4 | 455.6 | -84.5 | -16.6 | -10 | -- | 0.7 | |
| 11.0 | 1,747.6 | 1,892.6 | 144.7 | 15.5 | -21 | 12.9 | 9.6 | |
| 1.7 | 94.8 | 16.6 | -73.6 | -442.7 | -25.1 | -- | 0.4 | |
| 186.8 | 12,927.2 | 62,508.1 | 827.7 | 2.3 | 10 | 15.8 | 1.5 | |
| 1.3 | 164.0 | 7,022.0 | -1,029.0 | -6.9 | -105.6 | -- | 0.4 |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally.... The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California. Read more
Chairman of the Board & CEO
Dr. Xiaochun Xu M.B.A., Ph.D.
Chairman of the Board & CEO
Dr. Xiaochun Xu M.B.A., Ph.D.
Headquarters
Rancho Cordova, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Thermogenesis Holdings Inc (THMO) is $0.00 (NASDAQ) as of 02-Apr-2026 09:30 EDT. Thermogenesis Holdings Inc (THMO) has given a return of -96.63% in the last 3 years.
Since, TTM earnings of Thermogenesis Holdings Inc (THMO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.12
|
-0.61
|
|
2022
|
-0.29
|
1.00
|
|
2021
|
-0.02
|
0.08
|
|
2020
|
-0.03
|
0.09
|
|
2019
|
-0.06
|
0.62
|
The 52-week high and low of Thermogenesis Holdings Inc (THMO) are Rs 0.00 and Rs 0.00 as of 03-Apr-2026.
Thermogenesis Holdings Inc (THMO) has a market capitalisation of $ 0 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Thermogenesis Holdings Inc (THMO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.